Multiple Assemblies exist for SMTL entry 8stg
Discovery and clinical validation of RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations; X-RAY DIFFRACTION 3.79 Å

	SMTL ID 8stg.1 Ligands N-{4-[(5P)-4-amino-5-{3-fluoro-4-[(4-methylpyrimidin-2-yl)oxy]phenyl}-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl}-2-methylpropanamide Polypeptides Fibroblast growth factor receptor 2 Oligo-state monomer
	SMTL ID 8stg.2 Ligands N-{4-[(5P)-4-amino-5-{3-fluoro-4-[(4-methylpyrimidin-2-yl)oxy]phenyl}-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl}-2-methylpropanamide Polypeptides Fibroblast growth factor receptor 2 Oligo-state monomer